Carmen Marrero
Family Medicine · Loxahatchee, FLNPI 1215164926
Payments from drug & device makers
Across 199 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$838
- Novo Nordisk$452
- Boehringer Ingelheim$387
- Pfizer$354
- Amgen$331
- Abbott$288
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,84199%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $838 |
| Novo Nordisk | 25 | $452 |
| Boehringer Ingelheim | 21 | $387 |
| Pfizer | 20 | $354 |
| Amgen | 18 | $331 |
| Abbott | 3 | $288 |
| Merck | 16 | $244 |
| Lilly USA, LLC | 11 | $178 |
| AbbVie(2 entities) | 9 | $167 |
| GSK | 8 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Eisai Inc. | 5 | $79 |
| Amarin Pharma, Inc. | 3 | $58 |
| Shield Therapeutics Inc | 2 | $40 |
| Intuitive Surgical | 1 | $31 |
| Exact Sciences | 1 | $29 |
| Cardiovascular Systems Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Optinose US, Inc. | 1 | $22 |
| Gilead | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MERLIN@HOME$151
- Confirm Rx$117
- Ozempic$115
How this compares
$3,865 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $86,135 |
| EliquisApixaban | 78 | $81,792 |
| JardianceEmpagliflozin | 43 | $53,250 |
| MounjaroTirzepatide | 44 | $50,829 |
| XareltoRivaroxaban | 26 | $29,616 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $22,501 |
| LinzessLinaclotide | 12 | $15,599 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 107 | $11,791 |
| FarxigaDapagliflozin Propanediol | 17 | $11,564 |
| TrulicityDulaglutide | 12 | $10,977 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,889 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 177 | $5,232 |
| Rosuvastatin Calcium | 399 | $4,565 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,166 |
| Atorvastatin Calcium | 405 | $4,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $452 | $86,13575 claims |
| PfizerEliquis | $354 | $81,79278 claims |
| Lilly USA, LLCMounjaro, Trulicity | $178 | $61,80656 claims |
| Boehringer IngelheimJardiance | $387 | $53,25043 claims |
| Johnson & JohnsonXarelto | $23 | $29,61626 claims |
| AstraZenecaFarxiga, Symbicort | $838 | $15,73031 claims |
| AbbVieLinzess | $167 | $15,59912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Loxahatchee
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.